{"pmid":32448895,"title":"IBD in the Times of COVID-19.","text":["IBD in the Times of COVID-19.","Inflamm Bowel Dis","Hernandez Benabe, Stefany","Langshaw, Amber H","32448895"],"journal":"Inflamm Bowel Dis","authors":["Hernandez Benabe, Stefany","Langshaw, Amber H"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32448895","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1093/ibd/izaa132","keywords":["covid-19","inflammatory bowel disease","telemedicine"],"topics":["Prevention"],"weight":1,"_version_":1667785213906780160,"score":9.490897,"similar":[{"pmid":32438763,"title":"Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic.","text":["Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic.","Anemia is a frequent manifestation in patients with chronic inflammatory bowel disease (IBD) and requires tight monitoring and adequate supplementary therapy. Intravenous iron is the first-line treatment in subjects with moderate-severe anemia, active disease, or oral iron intolerance. On the other hand, oral iron is recommended in patients with mild anemia and inactive disease. However, during the current coronavirus pandemic, hospital activities have significantly changed, and all non-essential procedures, including non-urgent iron infusions, have been rescheduled. Oral iron, including both the traditional formulations with ferrous iron and the new ferric iron complexes, could constitute a valid alternative for anemia treatment. For this reason, we conducted a literature review, to summarize the scientific evidence on oral iron therapy in IBD patients with anemia.","J Clin Med","D'Amico, Ferdinando","Peyrin-Biroulet, Laurent","Danese, Silvio","32438763"],"abstract":["Anemia is a frequent manifestation in patients with chronic inflammatory bowel disease (IBD) and requires tight monitoring and adequate supplementary therapy. Intravenous iron is the first-line treatment in subjects with moderate-severe anemia, active disease, or oral iron intolerance. On the other hand, oral iron is recommended in patients with mild anemia and inactive disease. However, during the current coronavirus pandemic, hospital activities have significantly changed, and all non-essential procedures, including non-urgent iron infusions, have been rescheduled. Oral iron, including both the traditional formulations with ferrous iron and the new ferric iron complexes, could constitute a valid alternative for anemia treatment. For this reason, we conducted a literature review, to summarize the scientific evidence on oral iron therapy in IBD patients with anemia."],"journal":"J Clin Med","authors":["D'Amico, Ferdinando","Peyrin-Biroulet, Laurent","Danese, Silvio"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32438763","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.3390/jcm9051536","keywords":["covid-19","anemia","inflammatory bowel disease","iron deficiency","oral iron"],"e_drugs":["Iron"],"topics":["Prevention"],"weight":1,"_version_":1667523504877076481,"score":74.7351},{"pmid":32303609,"title":"Covid-19 and immunomodulation in IBD.","text":["Covid-19 and immunomodulation in IBD.","The current coronavirus pandemic is an ongoing global health crisis due to covid-19, caused by severe acute respiratory syndrome coronavirus 2. Although covid-19 leads to little or mild flu-like symptoms in the majority of affected patients, the disease may cause severe, frequently lethal complications such as progressive pneumonia, acute respiratory distress syndrome and organ failure driven by hyperinflammation and a cytokine storm syndrome. This situation causes various major challenges for gastroenterology. In the context of IBD, several key questions arise. For instance, it is an important question to understand whether patients with IBD (eg, due to intestinal ACE2 expression) might be particularly susceptible to covid-19 and the cytokine release syndrome associated with lung injury and fatal outcomes. Another highly relevant question is how to deal with immunosuppression and immunomodulation during the current pandemic in patients with IBD and whether immunosuppression affects the progress of covid-19. Here, the current understanding of the pathophysiology of covid-19 is reviewed with special reference to immune cell activation. Moreover, the potential implications of these new insights for immunomodulation and biological therapy in IBD are discussed.","Gut","Neurath, Markus F","32303609"],"abstract":["The current coronavirus pandemic is an ongoing global health crisis due to covid-19, caused by severe acute respiratory syndrome coronavirus 2. Although covid-19 leads to little or mild flu-like symptoms in the majority of affected patients, the disease may cause severe, frequently lethal complications such as progressive pneumonia, acute respiratory distress syndrome and organ failure driven by hyperinflammation and a cytokine storm syndrome. This situation causes various major challenges for gastroenterology. In the context of IBD, several key questions arise. For instance, it is an important question to understand whether patients with IBD (eg, due to intestinal ACE2 expression) might be particularly susceptible to covid-19 and the cytokine release syndrome associated with lung injury and fatal outcomes. Another highly relevant question is how to deal with immunosuppression and immunomodulation during the current pandemic in patients with IBD and whether immunosuppression affects the progress of covid-19. Here, the current understanding of the pathophysiology of covid-19 is reviewed with special reference to immune cell activation. Moreover, the potential implications of these new insights for immunomodulation and biological therapy in IBD are discussed."],"journal":"Gut","authors":["Neurath, Markus F"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303609","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1136/gutjnl-2020-321269","keywords":["cytokines","inflammation","inflammatory bowel disease"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138491068612608,"score":73.88771},{"pmid":32314792,"pmcid":"PMC7188155","title":"Challenges in the Care of IBD Patients During the CoViD-19 Pandemic: Report From a \"Red Zone\" Area in Northern Italy.","text":["Challenges in the Care of IBD Patients During the CoViD-19 Pandemic: Report From a \"Red Zone\" Area in Northern Italy.","Inflamm Bowel Dis","Occhipinti, Vincenzo","Pastorelli, Luca","32314792"],"journal":"Inflamm Bowel Dis","authors":["Occhipinti, Vincenzo","Pastorelli, Luca"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314792","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1093/ibd/izaa084","keywords":["covid-19","milan/lombardia","disease management","inflammatory bowel disease"],"topics":["Prevention"],"weight":1,"_version_":1666138493505503233,"score":64.18099},{"pmid":32211765,"pmcid":"PMC7184487","title":"Inflammatory bowel disease care in the COVID-19 pandemic era: the Humanitas, Milan experience.","text":["Inflammatory bowel disease care in the COVID-19 pandemic era: the Humanitas, Milan experience.","The outbreak of the COVID-19 caused by Coronavirus SARS-CoV2, is rapidly spreading worldwide. This is the first pandemic caused by a Coronavirus in history. More than 150,000 confirmed cases worldwide are reported by the SARS-CoV2, with more than 5,000 COVID-19-related deaths on March 14th, 2020. Fever, chills, cough, shortness of breath, generalized myalgia, malaise, drowsy, diarrhoea, confusion, dyspnoea, and bilateral interstitial pneumonia are the common symptoms. No therapies are available, and the only way to contain the virus spread is to regularly and thoroughly clean oneself hands with an alcohol-based hand rub or wash them with soap and water, to maintain at least 1 metre (3 feet) distance from anyone who is coughing or sneezing, to avoid touching eyes, nose and mouth, and to stay home if one feels unwell. No data are available on the risk of COVID-19 and outcomes in inflammatory bowel disease (IBD) patients. Outbreak restrictions can impact on the IBD care. We aim to give a viewpoint on how operationally manage IBD patients ensuring quality of care in the current pandemic era.","J Crohns Colitis","Fiorino, Gionata","Allocca, Mariangela","Furfaro, Federica","Gilardi, Daniela","Zilli, Alessandra","Radice, Simona","Spinelli, Antonino","Danese, Silvio","32211765"],"abstract":["The outbreak of the COVID-19 caused by Coronavirus SARS-CoV2, is rapidly spreading worldwide. This is the first pandemic caused by a Coronavirus in history. More than 150,000 confirmed cases worldwide are reported by the SARS-CoV2, with more than 5,000 COVID-19-related deaths on March 14th, 2020. Fever, chills, cough, shortness of breath, generalized myalgia, malaise, drowsy, diarrhoea, confusion, dyspnoea, and bilateral interstitial pneumonia are the common symptoms. No therapies are available, and the only way to contain the virus spread is to regularly and thoroughly clean oneself hands with an alcohol-based hand rub or wash them with soap and water, to maintain at least 1 metre (3 feet) distance from anyone who is coughing or sneezing, to avoid touching eyes, nose and mouth, and to stay home if one feels unwell. No data are available on the risk of COVID-19 and outcomes in inflammatory bowel disease (IBD) patients. Outbreak restrictions can impact on the IBD care. We aim to give a viewpoint on how operationally manage IBD patients ensuring quality of care in the current pandemic era."],"journal":"J Crohns Colitis","authors":["Fiorino, Gionata","Allocca, Mariangela","Furfaro, Federica","Gilardi, Daniela","Zilli, Alessandra","Radice, Simona","Spinelli, Antonino","Danese, Silvio"],"date":"2020-03-27T11:00:00Z","year":2020,"_id":"32211765","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1093/ecco-jcc/jjaa058","keywords":["covid-19","coronavirus","inflammatory bowel disease","pandemic","quality of care"],"locations":["Humanitas","Milan"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"e_drugs":["Alcohols","Water"],"topics":["Prevention"],"weight":1,"_version_":1666138492364652544,"score":41.327484},{"pmid":32305331,"pmcid":"PMC7161529","title":"Inflammatory bowel diseases and COVID-19: the invisible enemy.","text":["Inflammatory bowel diseases and COVID-19: the invisible enemy.","Gastroenterology","D'Amico, Ferdinando","Peyrin-Biroulet, Laurent","Danese, Silvio","32305331"],"journal":"Gastroenterology","authors":["D'Amico, Ferdinando","Peyrin-Biroulet, Laurent","Danese, Silvio"],"date":"2020-04-20T11:00:00Z","year":2020,"_id":"32305331","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1053/j.gastro.2020.04.032","keywords":["covid-19","coronavirus","inflammatory bowel disease","prevention"],"topics":["Prevention"],"weight":1,"_version_":1666138493368139776,"score":41.327484}]}